Discrete steps to antibiotic resistance

Join Our Community of Science Lovers!

This article was published in Scientific American’s former blog network and reflects the views of the author, not necessarily those of Scientific American


I've been getting so exited about the awesome powers of bacteria on this blog lately that I've been neglecting to cover the nasty bacteria. More specifically the fascinating world of antibiotics, the antimicrobial elements that bacteria and fungi produce and that humans exploit, manufacture and synthesise in order to protect against bacterial infections.

Luckily a great paper (reference below) came out recently that explores three different types of antibiotic treatment and how bacteria have evolved to protect themselves from the antibiotic attack. Bacteria can evolve quickly, as they reproduce relatively fast, and can support a larger number of mutations within their cells than the average human or eukaryotic cell. This means that by the time most antibiotics officially hit the market somewhere in the bacterial kingdom a method of resistance already exists.

In order to study how bacteria evolve resistance, the researchers used a tool that they named the "morbidostat" (presumably "Death-counter" was already taken) to adjust the antibiotic concentration in the experimental growth media to ensure that the bacteria were always under a high evolutionary pressure to evolve resistance. This is important for studying bacteria that require multiple mutations in order to evolve the highest form of resistance. Using a fixed concentration of antibiotics would produce maybe one of two helpful mutations that give the mutated bacteria enough advantage to outcompete the non-mutated ones. Constantly adjusting the antibiotic concentration means that the bacteria are in a constant struggle for that extra edge of resistance to give them a selective advantage.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Using the morbidostat also means that the bacteria are kept at a low concentration (rather than the resistant bacteria out-competing everything else and then growing exponentially). This prevents nutrients from becoming a limiting factor as the culture only ever contains a managable number of bacteria.

Using the morbidostat to control the cell cultures, they then set up five parallel experiments for three different antibiotics; chloramphenicol, doxycycline and trimethoprim. Every day, they took a sample of the culture to examine the levels of resistance within the culture. They found that while resistance to chloramphenicol and doxycycline increased smoothly over time, resistance to trimethoprim increased in a stepwise fashion, with no changes for a couple of days and then a sudden jump in resistance.

On the final day of the experiment they took one colony from each sample and sequenced the whole genome to see what genetic changes had occurred. Despite the fact that both chloramphenicol and doxycycline target the ribosome, no mutation to the ribosome was seen. This is not surprising as the ribosome is an important piece of cellular equipment and not to be tampered with! Instead, all the mutations in these bacteria were involved in transport and membrane proteins. The bacteria were acquiring mutations that allowed them to shuttle the antibiotic out of the cell. Not only that but the shuttling mechanism wasn't hugely specific either; bacteria with chloramphenicol resistance were also resistant to doxycycline.

For trimethoprim on the other hand, all the mutations were found in the region of the protein that the antibiotic affects (the synthesis pathway of an important metabolic enzyme). Trimethoprim resistance therefore was not transferable, bacteria resistant to trimethoprim were unable to survive when challenged with chloramphenicol or doxycycline. The step-wise evolution was seen as the area for mutation was so small. Whereas there are many small mutations that can occur to improve the ability of the cell to shuttle antibiotics away, mutations that affect such a small specific area of DNA are quite rare. Hence the stepwise resistance rate; all the bacteria would be equally susceptible until one small mutation happened prompting the sudden fast growth of the resistant population and a sudden increase in resistance.

The full genome sequence of the bacteria doesn't just allow researchers to find out which genes have mutated, it could also help to explore the exact order in which they did, putting together a developing resistance profile for the antibiotic response. That kind of detail would require many more cultures and experiments, but the techniques are all in place!

---

Credit for image 1

Ref: Toprak, E., Veres, A., Michel, J., Chait, R., Hartl, D., & Kishony, R. (2011). Evolutionary paths to antibiotic resistance under dynamically sustained drug selection Nature Genetics, 44 (1), 101-105 DOI: 10.1038/ng.1034

About S.E. Gould

A biochemist with a love of microbiology, the Lab Rat enjoys exploring, reading about and writing about bacteria. Having finally managed to tear herself away from university, she now works for a small company in Cambridge where she turns data into manageable words and awesome graphs.

More by S.E. Gould

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe